Stephanie Lheureux
Overview
Explore the profile of Stephanie Lheureux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
3725
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Lucas A, Mansfield A, Lheureux S, OConnor C, Zamboni B, et al.
Clin Transl Sci
. 2025 Mar;
18(3):e70178.
PMID: 40051118
Anetumab ravtansine, like other ADC drugs, has high inter-patient variability in its pharmacokinetic (PK) and pharmacodynamic (PD) outcomes, which raises concerns about whether current dosing regimens are optimal for patients....
2.
Roudko V, Del Valle D, Radkevich E, Kelly G, Hui X, Patel M, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 40010771
Background: Antiangiogenics combined with immune checkpoint blockade have become standard of care for recurrent endometrial cancer after standard platinum-based chemotherapy. To dissect mechanisms and define biomarkers associated with clinical outcomes...
3.
Bauer S, Oza A, Lheureux S
Int J Gynecol Cancer
. 2025 Feb;
35(2):101662.
PMID: 39923639
No abstract available.
4.
Martorana F, Pavone G, Sessa C, Treglia G, Lheureux S, Colombo I
Int J Gynecol Cancer
. 2025 Jan;
35(1):100009.
PMID: 39878268
Objective: This systematic review analyzed phase III trials in platinum-resistant ovarian cancer to understand their poor outcomes and guide future trials. Methods: A systematic review adhering to PRISMA guidelines was...
5.
Alqaisi H, Cohn D, Chern J, Duska L, Jewell A, Corr B, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836408
Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization...
6.
Ishak C, Marhon S, Tchrakian N, Hodgson A, Loo Yau H, Gonzaga I, et al.
Cancer Discov
. 2025 Jan;
PMID: 39776167
Epigenetic therapies facilitate transcription of immunogenic repetitive elements that cull cancer cells through 'viral mimicry' responses. Paradoxically, cancer-initiating events also facilitate transcription of repetitive elements. Contributions of repetitive element transcription...
7.
Lee J, Tan D, Ray-Coquard I, Lee J, Kim B, Van Nieuwenhuysen E, et al.
J Gynecol Oncol
. 2024 Dec;
36(1):e51.
PMID: 39710508
Background: Recurrent gynecological clear cell carcinoma (rGCCC) has a low objective response rate (ORR) to chemotherapy. Previous preclinical and clinical data suggest a potential synergy between immune checkpoint inhibitors and...
8.
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, et al.
Genome Med
. 2024 Dec;
16(1):145.
PMID: 39695768
Background: The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors represented a paradigm shift in the treatment of ovarian cancer. Genomic data from patients with high-grade ovarian cancer in six phase II/III...
9.
Garg V, Ruiz Buenrostro A, Heuniken K, Bagnarol R, Yousef M, Sajewicz K, et al.
Cancer Med
. 2024 Dec;
13(23):e70450.
PMID: 39651705
Background: Novel systemic anticancer therapies (SACT) in the form of targeted and immunotherapies are increasingly replacing traditional chemotherapy. Little is known about the impact of novel SACT on healthcare resource...
10.
Marth C, Moore R, Bidzinski M, Pignata S, Ayhan A, Rubio M, et al.
J Clin Oncol
. 2024 Nov;
43(9):1083-1100.
PMID: 39591551
Purpose: Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) in the phase...